Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Cell and gene therapies are transforming outcomes, but complex manufacturing processes limit volumes, delay arrival on the market and raise prices.Optimizing production reduces costs per dose and improves access for patients.
From providing evidence to inform decisions on COVID-19 and recognizing outstanding scientists, to contributing to global scientific dialogue and promoting research integrity, the AAS fills a wide remit.
While developing an affordable electrocatalyst to underwrite green hydrogen energy, this Australian team has harnessed a ‘spillover’ effect to prevent a common reaction bottleneck.
Digital tools offer clinicians opportunities to have insights on a patient’s treatment journey, and allow patients to be more involved in their treatment
Infections in health-care settings continue to rise. Scientists and health-care providers are turning to next-generation sequencing to detect outbreaks and guide implementation of targeted interventions.
Monoclonal antibodies are a prized asset in drug development, but developing and producing them at the right quality and scale requires a firm grasp of working with mammalian cell cultures.
The translation of life science research into novel biotherapeutic and diagnostic solutions will require team efforts from academia, industry, and government.
COVID-19 vaccine logistics have highlighted the value and challenges of the cold chain. Manufacturers must balance performance with improved sustainability.
At a new institute that bears his name, immunologist and Nobel laureate James P. Allison aims to drive groundbreaking interdisciplinary science to deliver impactful breakthroughs.